Vivos Therapeutics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $3.40M Miss $4.15M Estimate
Portfolio Pulse from Benzinga Newsdesk
Vivos Therapeutics reported Q2 losses of $(0.18) per share, missing the analyst consensus estimate of $(0.14) by 28.57%. The company also reported quarterly sales of $3.40 million, missing the analyst consensus estimate of $4.15 million by 18.19%. This represents a 45.45% increase in losses and an 18.86% decrease in sales compared to the same period last year.
August 16, 2023 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vivos Therapeutics reported higher than expected losses and lower than expected sales for Q2. This could negatively impact the company's stock price in the short term.
Vivos Therapeutics reported higher losses and lower sales than expected for Q2. This underperformance could lead to a decrease in investor confidence and a potential drop in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100